KR100978684B1 - Ｔｇｆ 베타 1 특이적 항체 - Google Patents

Ｔｇｆ 베타 1 특이적 항체 Download PDF

Info

Publication number
KR100978684B1
KR100978684B1 KR1020077024149A KR20077024149A KR100978684B1 KR 100978684 B1 KR100978684 B1 KR 100978684B1 KR 1020077024149 A KR1020077024149 A KR 1020077024149A KR 20077024149 A KR20077024149 A KR 20077024149A KR 100978684 B1 KR100978684 B1 KR 100978684B1
Authority
KR
South Korea
Prior art keywords
ser
thr
pro
tgf
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077024149A
Other languages
English (en)
Korean (ko)
Other versions
KR20070114220A (ko
Inventor
줄리안 데이비스
크레이그 듀안 디킨슨
리후아 후앙
브라이언 에드워드 존스
데이비드 매튜 마르퀴스
스콧 윌리엄 로린슨
잉 탕
피터 에드워드 바일란코트
제프리 딘 왓킨스
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20070114220A publication Critical patent/KR20070114220A/ko
Application granted granted Critical
Publication of KR100978684B1 publication Critical patent/KR100978684B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
KR1020077024149A 2005-04-22 2006-04-20 Ｔｇｆ 베타 1 특이적 항체 Expired - Fee Related KR100978684B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67408205P 2005-04-22 2005-04-22
US60/674,082 2005-04-22

Publications (2)

Publication Number Publication Date
KR20070114220A KR20070114220A (ko) 2007-11-29
KR100978684B1 true KR100978684B1 (ko) 2010-08-31

Family

ID=37192643

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077024149A Expired - Fee Related KR100978684B1 (ko) 2005-04-22 2006-04-20 Ｔｇｆ 베타 1 특이적 항체

Country Status (23)

Country Link
US (2) US7619069B2 (enExample)
EP (1) EP1874818B1 (enExample)
JP (1) JP5070200B2 (enExample)
KR (1) KR100978684B1 (enExample)
CN (1) CN101163719A (enExample)
AT (1) ATE505489T1 (enExample)
AU (1) AU2006240056B2 (enExample)
BR (1) BRPI0608376A8 (enExample)
CA (1) CA2607448C (enExample)
CY (1) CY1111518T1 (enExample)
DE (1) DE602006021292D1 (enExample)
DK (1) DK1874818T3 (enExample)
EA (1) EA016038B1 (enExample)
ES (1) ES2361269T3 (enExample)
HR (1) HRP20110334T1 (enExample)
IL (1) IL186775A (enExample)
NO (1) NO20076003L (enExample)
PL (1) PL1874818T3 (enExample)
PT (1) PT1874818E (enExample)
RS (1) RS51845B (enExample)
SI (1) SI1874818T1 (enExample)
UA (1) UA93201C2 (enExample)
WO (1) WO2006116002A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737519A1 (en) * 2008-09-29 2010-04-01 Centocor Ortho Biotech Inc. Anti-cd147 antibodies, methods, and uses
JP5735922B2 (ja) * 2008-11-22 2015-06-17 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
WO2010077831A1 (en) * 2008-12-16 2010-07-08 Tod Lauerman Targeted cytokine for treatment of diseases
CA3150199C (en) 2009-01-09 2025-07-22 Seagen Inc. WEEKLY DOSING REGIMEN FOR ANTI-CD30 ANTIBODY CONJUGATIONS VC-PAB-MMAE - MEDICINE
WO2012129330A1 (en) 2011-03-23 2012-09-27 Option Pharmaceutical, Llc Targeted cytokine for treatment of musculoskeletal diseases
HRP20211582T1 (hr) * 2011-06-03 2022-01-07 Xoma Technology Ltd. Protutijela specifična za tgf-beta
IN2014CN03555A (enExample) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
EP2822592B1 (en) 2012-03-08 2018-08-15 Ludwig Institute for Cancer Research Limited Tgf- 1 specific antibodies and methods and uses thereof
BR112014022200A2 (pt) 2012-03-08 2019-09-24 Selig Sealing Products Inc membro de vedação de recipiente com compodnente de segurança protegido e aba de remoção
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
KR102738546B1 (ko) * 2014-02-19 2024-12-04 메르크 파텐트 게엠베하 암-표적화된 ｉｌ-12 면역요법
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
EA201891724A1 (ru) 2016-02-17 2019-01-31 Новартис Аг Антитела к tgf-бета2
CN109415734B (zh) * 2016-02-26 2022-08-19 西安大略大学 抗CD11d抗体及其用途
MX2018010948A (es) 2016-03-11 2019-06-20 Scholar Rock Inc INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
AU2017268234A1 (en) 2016-05-17 2018-12-13 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
CA3025020A1 (en) * 2016-05-20 2017-11-23 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
TW201811827A (zh) * 2016-09-05 2018-04-01 日商中外製藥股份有限公司 抗ＴＧＦ－β１抗體及使用方法
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2020006511A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Trispecific antagonists
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
BR112021008873A8 (pt) 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
MX2021009175A (es) 2019-01-30 2021-09-14 Scholar Rock Inc Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
TW202135862A (zh) 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
MX2023015206A (es) * 2021-06-18 2024-03-25 Genzyme Corp Formulaciones de anticuerpos anti-tgf-beta y su uso.
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2000040227A2 (en) 1999-01-05 2000-07-13 University Of Utah Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
MXPA06014067A (es) 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands

Also Published As

Publication number Publication date
NO20076003L (no) 2008-01-22
CN101163719A (zh) 2008-04-16
EA200702278A1 (ru) 2008-08-29
US8128927B2 (en) 2012-03-06
US20100040633A1 (en) 2010-02-18
US20080050375A1 (en) 2008-02-28
EA016038B1 (ru) 2012-01-30
ATE505489T1 (de) 2011-04-15
SI1874818T1 (sl) 2011-08-31
JP5070200B2 (ja) 2012-11-07
WO2006116002A3 (en) 2007-02-01
EP1874818A2 (en) 2008-01-09
CY1111518T1 (el) 2015-08-05
PT1874818E (pt) 2011-05-05
UA93201C2 (ru) 2011-01-25
JP2008538564A (ja) 2008-10-30
DK1874818T3 (da) 2011-06-14
AU2006240056A1 (en) 2006-11-02
IL186775A0 (en) 2008-02-09
BRPI0608376A8 (pt) 2018-10-16
IL186775A (en) 2013-03-24
WO2006116002A9 (en) 2007-07-19
KR20070114220A (ko) 2007-11-29
CA2607448C (en) 2014-11-18
HRP20110334T1 (hr) 2011-06-30
RS51845B (sr) 2012-02-29
US7619069B2 (en) 2009-11-17
CA2607448A1 (en) 2006-11-02
DE602006021292D1 (de) 2011-05-26
EP1874818B1 (en) 2011-04-13
PL1874818T3 (pl) 2011-09-30
ES2361269T3 (es) 2011-06-15
WO2006116002A2 (en) 2006-11-02
BRPI0608376A2 (pt) 2010-11-16
AU2006240056B2 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
KR100978684B1 (ko) Ｔｇｆ 베타 1 특이적 항체
JP7065822B2 (ja) β‐クロトー、ＦＧＦ受容体、およびその複合体と結合するヒト抗原結合タンパク質
JP6513617B2 (ja) 脳疾患を治療するための抗タウｐＳ４２２抗体の使用
CA2781050C (en) Pcsk9 antagonists
WO2005010049A2 (en) Tgf-beta1 ligands
JP2020508054A (ja) 抗タウ抗体及びその使用方法
IL295980A (en) Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
US20200231672A1 (en) Single chain variable fragment cd3 binding proteins
KR102709785B1 (ko) Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용
JP2014530608A (ja) 抗ｓＰＬＡ２−Ｖ抗体およびその使用
US8207307B2 (en) Antibodies against human CCN1 and uses thereof
JP7643727B2 (ja) 抗－ｆｇｆ１９抗体
HK1119183A (en) Tgf beta 1 specific antibodies
WO2023242634A1 (en) Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass
KR20250057832A (ko) 갑상선 자극 호르몬 수용체에 결합하는 항체 및 이의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20130729

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20140730

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170824

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170824